Literature DB >> 20822033

Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention?

Matthew Butts1, Aminah Jatoi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20822033      PMCID： PMC6015759     

Source DB:  PubMed          Journal:  J Support Oncol        ISSN： 1544-6794


× No keyword cloud information.
  2 in total

1.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

2.  Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.

Authors:  Bret Wacker; Tina Nagrani; Jacqueline Weinberg; Karsten Witt; Gary Clark; Pablo J Cagnoni
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531
  2 in total
  1 in total

1.  Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study.

Authors:  Cécile Charles; Darius Razavi; Catherine Bungener; Christine Mateus; Emilie Lanoy; Michèle Verschoore; Sarah Dauchy; Caroline Robert
Journal:  Clin Drug Investig       Date:  2016-03       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.